|
|
|
| Efficacy of Dapagliflozin Combined with Enalapril in the Treatment of Patients with Diabetic Nephropathy |
| ZHOU Yuanting |
| Department of Internal Medicine, the Third People's Hospital of Zhenping County, Nanyang Henan 474272 |
|
|
|
|
Abstract 【Objective】 To investigate the efficacy of dapagliflozin combined with enalapril in the treatment of patients with diabetic nephropathy (DN). 【Methods】 A total of 93 patients with DN admitted to our hospital from February 2022 to November 2025 were enrolled. According to different treatment methods, they were divided into a control group (n=47, treated with enalapril) and an observation group (n=46, treated with dapagliflozin combined with enalapril). The clinical efficacy of the two groups was compared, as well as blood glucose indices [fasting blood glucose (FPG), glycated hemoglobin (HbA1c)], renal function indices [β2-microglobulin (β2-MG), cystatin C (cys C), homocysteine (Hcy)], inflammatory markers [intercellular adhesion molecule-1 (ICAM-1), serum amyloid A (SAA), interleukin-6 (IL-6)], oxidative stress indices [total antioxidant capacity (TAOC), malondialdehyde (MDA), superoxide dismutase (SOD)], and safety before and after treatment. 【Results】 After treatment, the efficacy in the observation group was higher than that in the control group (P<0.05). The levels of FPG, HbA1c, β2-MG, cys C, Hcy, ICAM-1, SAA, IL-6, and MDA in both groups were lower than those before treatment (P<0.05);Furthermore, those levels in the observation group were lower than those in the control group (P<0.05). The levels of TAOC and SOD in both groups were higher than those before treatment (P<0.05), and both TACO and SOD levels in the observation group were higher than those in the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Dapagliflozin combined with enalapril in the treatment of DN patients can effectively improve clinical efficacy by reducing blood glucose levels, alleviating inflammatory response and oxidative stress, and promoting the recovery of renal function, with good safety.
|
|
Received: 17 March 2026
|
|
|
|
|
|
[1] 陈青苗,陈岳尧,周仕群,等. 低剂量西格列汀联合卡格列净治疗糖尿病肾病的疗效及对炎症指标、氧化应激反应的影响[J].中国医院用药评价与分析,2023,23(11):1313-1316.
[2] 李翠翠,季小勇. 芪参益气滴丸联合依那普利治疗对糖尿病肾病患者血清IL-6、SAA和TNF-α水平的影响[J].检验医学与临床,2022,19(2):246-248.
[3] 邹俊杰,郭嘉惠,殷汉,等. 卡格列净联合依那普利治疗糖尿病肾病患者的临床研究[J].中国临床药理学杂志,2024,40(9):1248-1251.
[4] 施建锋.达格列净联合依那普利治疗2型糖尿病肾病的临床分析[J].罕少疾病杂志,2025,32(10):146-149.
[5] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.
[6] 中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏病防治指南(2021年版)[J].中华糖尿病杂志,2021,13(8):762-784.
[7] 李西胜,马世兴,王勤超. 高通量与低通量血液透析治疗糖尿病肾病的效果及对患者血GSH-Px、MDA、SOD水平的影响[J].海南医学,2022,33(19):2467-2470.
[8] DAWOOD M H, ABDULRIDHA M K, QASIM H S. Assessing pyridoxine adjuvant therapy effects on blood glucose levels in type 2 diabetes: a randomized clinical trial[J].J Med Life,2023,16(10):1474-1481.
[9] UEMURA T, NISHIMOTO M, ERIGUCHI M, et al. Utility of serum β2-microglobulin for prediction of kidney outcome among patients with biopsy-proven diabetic nephropathy[J].Diabetes Obes Metab,2024,26(2):583-591.
[10] CAO X, PEI X M. Developing screening tools to estimate the risk of diabetic kidney disease in patients with type 2 diabetes mellitus[J].Technol Health Care,2024,32(3):1807-1818.
[11] 梁爽,郭贺,李洪军. 血尿酸、血同型半胱氨酸与糖尿病肾病相关性的研究进展[J].中国实验诊断学,2023,27(2):231-234.
[12] 黄丹,胡韬韬,陈丹. 血清高迁移率族蛋白B1与糖尿病肾病病人肾功能、炎症因子及氧化应激指标的相关性研究[J].蚌埠医学院学报,2022,47(8):1021-1025.
[13] 何霁,孙娜,袁宁,等. 外周血SFRP1、SAA检测在早期糖尿病肾病诊断中的价值[J].国际检验医学杂志,2021,42(4):493-496.
[14] 戚筱妹,黄国东. 益气通络方联合达格列净对早期糖尿病肾病患者氧化应激和炎症反应的影响[J].微循环学杂志,2023,33(2):80-84. |
|
|
|
2026, Vol. 43 
